CCR5 and myeloid sarcoma: Analyzing the expression of brain residency-associated T cell markers after one year of OCR treatment in PP-MS patients, van Puijfelik et al. reported a prominent loss of CXCR3+ and CCR5+ CD4+ and CD8+ T cell memory fractions compared to untreated PP-MS [33].